Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
165,5 SEK | +0,49% | +4,42% | +23,78% |
25/04 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
25/04 | Biotage AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 | CI |
Attività
Numero di dipendenti: 669
Vendite per attività
SEK in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Small Molecules & Synthetic Therapeutics
35,1
%
| 770 | 49,1 % | 654 | 35,1 % | -15,06% |
Biologics & Advanced Therapeutics
24,4
%
| 66 | 4,2 % | 454 | 24,4 % | +587,88% |
Analytical Testing
22,3
%
| 382 | 24,4 % | 415 | 22,3 % | +8,64% |
Scale-up
8,2
%
| 181 | 11,6 % | 152 | 8,2 % | -16,02% |
Water & Environmental Testing
7,1
%
| 122 | 7,8 % | 133 | 7,1 % | +9,02% |
Diagnostics
2,9
%
| 46 | 2,9 % | 54 | 2,9 % | +17,39% |
Vendite per regione
SEK in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
North and South America
40,2
%
| 660 | 42,1 % | 748 | 40,2 % | +13,33% |
EMEA
39,2
%
| 376 | 24,0 % | 729 | 39,2 % | +93,88% |
China
7,5
%
| 232 | 14,8 % | 139 | 7,5 % | -40,09% |
Japan
6,0
%
| 115 | 7,3 % | 111 | 6,0 % | -3,48% |
South Korea
3,2
%
| 61 | 3,9 % | 60 | 3,2 % | -1,64% |
Other APAC
1,8
%
| - | - | 33 | 1,8 % | - |
India
1,5
%
| 32 | 2,0 % | 27 | 1,5 % | -15,62% |
Sweden
0,8
%
| 18 | 1,1 % | 15 | 0,8 % | -16,67% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 72 | 09/02/06 | |
Andrew Kellett
DFI | Director of Finance/CFO | 56 | 25/09/23 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Magnus Nordstedt
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/01/02 |
Anders Wikström
COO | Chief Operating Officer | 51 | 01/10/02 |
Lisa Egelrud
LAW | General Counsel | 49 | - |
Sales & Marketing | 50 | - | |
Olof Nord
PRN | Corporate Officer/Principal | 49 | - |
Petra Duprez
HRO | Human Resources Officer | 59 | 01/05/20 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 72 | 09/02/06 | |
Åsa Hedin
BRD | Director/Board Member | 62 | 01/11/19 |
Kieran Murphy
CHM | Chairman | 61 | 04/01 |
Director/Board Member | 69 | - | |
Mark Bradley
BRD | Director/Board Member | 62 | 24/04/19 |
Karen Sørensen
BRD | Director/Board Member | 62 | - |
Daniel Menasco
BRD | Director/Board Member | 47 | 01/01/15 |
Pär Lundgren
BRD | Director/Board Member | 39 | - |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 80 008 185 | 79 645 985 ( 99,55 %) | 0 | 99,55 % |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Biotage Sweden AB
Biotage Sweden AB Medical SpecialtiesHealth Technology Part of Biotage AB, Biotage Sweden AB is a Swedish impact tech company committed to solving society ’ s problems. The private company is based in Uppsala, Sweden. The company offers solutions in drug discovery, analytical, water, and environmental testing. Biotage provides workflow solutions and products to customers in drug discovery and development, analytical testing, and water and environmental testing. The company was founded in 1989 by Sheridan G. Snyder. |
Medical Specialties
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+23,78% | 1,21 Mrd | |
-12,91% | 19,08 Mrd | |
-46,21% | 2,65 Mrd | |
+18,15% | 1,87 Mrd | |
-3,12% | 1,61 Mrd | |
-10,69% | 1,02 Mrd | |
-20,89% | 905 Mln | |
-7,14% | 716 Mln | |
-18,10% | 682 Mln | |
+4,01% | 480 Mln |
- Borsa valori
- Azioni
- Azione BIOT
- Società Biotage AB